Streetbeat News

Analyst Ratings

DASH

Wells Fargo analyst Ken Gawrelski maintains an Equal-Weight rating on DoorDash and raises the price target from $127 to $142.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:18 pm

META

Meta Platforms has seen a surge in options activity, with a notable bearish sentiment among traders. Despite this, analysts maintain high price targets, indicating potential growth. The stock is currently trading at $584.58, with a slight increase of 0.31%.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:16 pm

IREN

Iris Energy Limited (NASDAQ:IREN) reported a 42% increase in revenue for September, mining 347 Bitcoin and reducing electricity costs by 21%. The company expanded its GPU fleet and aims to increase capacity to 31 EH/s by Q4 2024. Analysts maintain positive ratings with a price target of $16.5.

Portfolio Pulse from Erica Kollmann

October 04, 2024 | 2:16 pm

JPM

Deep-pocketed investors are showing significant interest in JPMorgan Chase (NYSE:JPM) options, with a mix of bullish and bearish sentiments. The options activity suggests a focus on a price range between $150 and $220. Analysts maintain positive ratings with price targets up to $234.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 2:16 pm

PEP

Barclays analyst Lauren Lieberman maintains an Overweight rating on PepsiCo but slightly lowers the price target from $187 to $186.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:13 pm

LW

Barclays analyst Andrew Lazar maintains an Overweight rating on Lamb Weston Holdings (NYSE:LW) and raises the price target from $70 to $74.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:12 pm

MS

Morgan Stanley shares rise as HSBC upgrades the stock from Hold to Buy, setting a $118 price target.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:12 pm

DKNG

Barclays analyst Brandt Montour has maintained an Overweight rating on DraftKings and raised the price target from $43 to $45.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:10 pm

CVS

CVS Health shares rose following an upgrade by TD Cowen from Hold to Buy, with a price target increase from $59 to $85.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:10 pm

BMRN

Barclays analyst Gena Wang maintains an Overweight rating on Biomarin Pharmaceutical but lowers the price target from $110 to $86.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 2:08 pm